ReviewFuture science OA2018
Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature.
Review in Future science OA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed.
- Diagnosis of Parapneumonia Pleural Effusion with Serum and Pleural Fluid Cell-Free DNA.BioMed research international · 2019Trial
- Circulating Cell-Free DNA in Psychiatric Disorders: Current Evidence, Inflammation-Based Stratification, and Future Perspectives.International journal of molecular sciences · 2026Review
- Review
- Navigating the molecular landscape: integrated multiomics liquid biopsy for biomarker discovery in early detection and monitoring of colorectal cancer.Frontiers in molecular biosciences · 2026Review
- Review
- A prediction model based on cfDNA concentration and cfDNA methylation biomarkers for lung cancer detection.Scientific reports · 2025Article
- Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing.NPJ systems biology and applications · 2025Article
- Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.International journal of molecular sciences · 2025Review
- Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.International journal of molecular sciences · 2025Review
- Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.International journal of molecular sciences · 2025Review
- Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons.BMC medical genomics · 2025Article
- Improvement of the sensitivity of circulating tumor DNA-based liquid biopsy: current approaches and future perspectives.Exploration of targeted anti-tumor therapy · 2025Review
- Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.Cancers · 2024Review
- An Investigation into Cell-Free DNA in Different Common Cancers.Molecular biotechnology · 2024Review
- Article
- Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons.Research square · 2024Article
- Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.MedComm · 2024Review
- Donor-derived cell-free DNA is a valuable monitoring tool after single lung transplantation: Multicenter analysis.JHLT open · 2024Article
- First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments.Journal for immunotherapy of cancer · 2024Article
- Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating cell-free DNA is considered as one of the major breakthroughs in the field of innovative diagnosis, used as a liquid biopsy. The kinetic parameters of a biomarker are mandatory to assess its usefulness as a diagnostic tool. Obtaining precise mathematical values for the kinetic parameters (e.g., half-life) is then crucial because it could be used for therapeutic monitoring as a prognostic factor. However, little is known about the intrinsic properties of circulating cell-free DNA, more especially, its kinetic properties within the organism. We summarized the basic principles that may affect the kinetics of circulating cell-free DNA within the organism in the light of biological and clinical evidence. We also meta-analyzed the reported data in the literature and the methodologies that have been used to study the kinetic parameters of human circulating cell-free DNA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.